Industry Supported Sessions’ Timetable

Wednesday April 1, 2020
DATA SCIENCE AND DIGITAL HEALTH FOR NEURODEGENERATIVE DISORDERS
9:00- 16:45		Hall F1

Thursday, April 2, 2020
DIAGNOSING ALZHEIMER’S DISEASE: OVERCOMING THE OBSTACLES (not included in main event CME/CPD credit)
14:05 – 16:00	Symposium Organized by BIOGEN Chair: Philip Scheltens, The Netherlands	Hall E
14:05	Welcome and introduction Philip Scheltens, The Netherlands
14:10	Meet our patient: a complex case at a young age Philip Scheltens, The Netherlands
14:15	Cognitive differences between subtypes of AD John Harrison, UK
14:35	Exploring imaging biomarkers in the diagnosis of AD across the age span Tammie Benzinger, USA
14:55	A review of AD pathology across the age range Dietmar Thal, Belgium
15:15	Summary and close Philip Scheltens, The Netherlands

Friday, April 3, 2020
PREPARING NOW FOR A FUTURE WITH DISEASE-MODIFYING THERAPIES IN ALZHEIMER’S DISEASE (not included in main event CME/CPD credit)
11:05 – 13:00	Symposium Organized by ROCHE Chair: Philip Scheltens, The Netherlands	Hall E
11:05	Welcome and introduction Philip Scheltens, The Netherlands
11:15	Which approaches could improve the journey of the AD patient and caregiver in the near future? Paola Barbarino, UK
11:40	How can diagnosing the right patients at the right time support effective use of Disease-Modifying Therapies? Anne Fagan, USA
12:05	What are the key challenges and opportunities for Amyloid-Targeted Disease-Modifying Therapies? Alessandro Padovani, Italy
12:30	Q&A session All faculty
12:50	Summary and meeting close Philip Scheltens, Netherlands

CHANGING THE COURSE OF PARKINSON’S DISEASE: THE POTENTIAL OF DISEASE-MODIFYING THERAPIES (not included in main event CME/CPD credit)
15:40 – 16:40	Symposium Organized by ROCHE Chair: Josefa Domingos, The Netherlands	Hall E
15:40	Welcome and introduction Josefa Domingos, The Netherlands
15:50	Unmet needs in PD Josefa Domingos, The Netherlands
16:00	What do disease-modifying therapies mean to you Wilma van de Berg, The Netherlands and Josefa Domingos, The Netherlands
16:10	The role of α-synuclein in PD Wolfgang Oertel, Germany and Wilma van de Berg, The Netherlands
16:20	α-synuclein as a target for disease-modifying therapies Wilma van de Berg, The Netherlands and Josefa Domingos, The Netherlands
16:25	Close Josefa Domingos, The Netherlands

Saturday, April 4, 2020
SPONSORED SYMPOSIUM 5 (not included in main event CME/CPD credit)
11:05 – 13:00		Hall E

MASUPIRDINE (SUVN-502) – POTENTIAL BENEFITS IN COGNITION AND NEUROPSYCHIATRIC SYMPTOMS IN PATIENTS WITH ALZHEIMER’S DISEASE (not included in main event CME/CPD credit)
15:35 – 16:45	Symposium Organized by SUVEN Chair: Jeffrey Cummings, USA	Hall E
15:35	WELCOME AND INTRODUCTION Jeffrey Cummings, USA
15:45	POTENTIAL SIGNALS OF BENEFIT FOR MASUPIRDINE ON COGNITION, FUNCTION, AND GLOBAL PROGRESSION IN ALZHEIMER’S DISEASE: EXPLORATORY ANALYSES AND IMPLICATIONS Alireza Atri, USA
16:05	POTENTIAL BENEFITS OF MASUPIRDINE ON NEUROPSYCHIATRIC SYMPTOMS IN PATIENTS WITH ALZHEIMER’S DISEASE Clive Ballard, UK
16:25	PANEL DISCUSSION / QUESTIONS AND ANSWERS Jeffrey Cummings, USA Clive Ballard, UK Alireza Atri, USA